ALK-Abello Allergy Treatment R&D

Projektträger – zwischengeschaltetes Finanzinstitut

ALK-Abello A/S

Ort

• Dänemark

Beschreibung

The project consists of Alk Abello's R&D activities, particularly those related to the development tablet based treatments for trees and ragweed pollen allergy, house dust mite and cat allergy and to the development of scientific models that lead to a better understanding of the immunological mechanisms of allergy and vaccination therapy, which can be used in next generation immuno-allergy vaccines. The project will be implemented in the period 2009-2010.

Ziele

The project should strengthen the market position of one of the EU-based market leaders, operating in the global market for allergen immunotherapy.

Sektor(en)

• Industrie

Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)

EUR 40 million.

Gesamtkosten (voraussichtlicher Betrag)

EUR 97.5 million.

Umweltaspekte

The project is expected to have no significant environmental impact.

Auftragsvergabe

Procurement is in line with EIB guidelines for the private sector projects.

Projektstatus

Unterzeichnet - 10/06/2010